Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Amgen is a global biotechnology company operating in a single segment: human therapeutics. The company discovers, develops, manufactures, and delivers innovative medicines for serious diseases. In 2024, Amgen advanced its pipeline, expanded its manufacturing network, and integrated the Horizon Therapeutics acquisition completed in October 2023.
Key Financial Metrics
| Metric (in millions) | 2024 | 2023 | Change |
|---|---|---|---|
| Total Revenues | $33,424 | $28,190 | +19% |
| Product Sales | $32,026 | $26,910 | +19% |
| Operating Income | $7,258 | $7,897 | -8% |
| Net Income | $4,090 | $6,717 | -39% |
| Diluted EPS | $7.56 | $12.49 | -39% |
| Operating Cash Flow | $11,490 | $8,471 | +36% |
| Capital Expenditures | $1,096 | $1,112 | -1% |
| Total Debt (Carrying Value) | $60,099 | $64,613 | -7% |
| Cash and Cash Equivalents | $11,973 | $10,944 | +9% |
Margins: Operating margin decreased to 21.7% in 2024 from 28.0% in 2023. Cost of sales increased to 38.5% of total revenues, driven by amortization of Horizon acquisition assets.
Material Changes vs. Prior Period
- Revenue Growth: Total product sales increased 19%, driven by 23% volume growth. This was partially offset by a 2% decline in net selling price. Horizon products contributed $4.2 billion in 2024 sales compared to $954 million in 2023.
- Profitability Decline: Net income dropped 39% primarily due to a significant decrease in "Other income (expense), net." In 2023, this line item included $1.2 billion in unrealized gains from the BeiGene investment reclassification. In 2024, this turned into a net unrealized loss.
- Expense Increases: Operating expenses rose 29% to $26.2 billion. R&D expenses increased 25% to $6.0 billion, and SG&A increased 15% to $7.1 billion, reflecting Horizon integration costs and higher clinical spend.
- Debt Reduction: The company repaid $3.6 billion of debt in 2024, including the full repayment of the April 2025 term loan and the 3.625% 2024 Notes.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- 2025 Expectations: Management expects volume growth from certain brands to be partially offset by net selling price declines. First-quarter sales are historically lower due to plan changes and deductible resets.
- Capital Allocation: The company continues to invest in manufacturing expansion (estimated $2.3 billion in 2025 capex) while reducing debt and returning capital via dividends and share repurchases. The quarterly dividend was increased 6% to $2.25 per share in 2024, with a further 6% increase declared for Q1 2025.
- Manufacturing: New facilities in North Carolina and Ohio are coming online to increase biologics capacity.
Key Risks and Contingencies:
- Patent Expirations: Patents for Prolia and XGEVA expire in February 2025 in the U.S. and November 2025 in select European countries. The company expects sales erosion from biosimilar competition in 2025.
- IRA Price Setting: ENBREL is subject to Medicare price setting starting January 1, 2026, and Otezla starting January 1, 2027. This is expected to negatively impact profitability for these products.
- Tax Litigation: Amgen is contesting IRS Notices of Deficiency for tax years 2010–2015 regarding profit allocation between the U.S. and Puerto Rico. The trial concluded in January 2025, with a decision expected no earlier than 2026. Potential additional tax liabilities could exceed $8 billion plus interest and penalties.
- Legal Proceedings: Ongoing patent litigation regarding Repatha (vs. Sanofi/Regeneron) and biosimilar challenges for Prolia/XGEVA (vs. Celltrion, Samsung, Fresenius, Accord).
Investor Verification Checklist
- Biosimilar Impact: Verify the actual sales erosion trajectory for Prolia and XGEVA in Q1 2025 following patent expiration.
- Tax Court Outcome: Monitor the U.S. Tax Court decision expected in 2026 regarding the Puerto Rico transfer pricing dispute, which could materially impact future earnings.
- IRA Pricing: Track the final negotiated Medicare prices for ENBREL (effective 2026) and Otezla (effective 2027) to assess long-term margin pressure.
- Horizon Integration: Assess whether Horizon products (TEPEZZA, KRYSTEXXA, UPLIZNA) continue to meet growth projections and integration synergies.
- Debt Servicing: Confirm the company's ability to service its remaining ~$60 billion debt load while maintaining dividend growth and capital expenditures.